Literature DB >> 26795727

Novel mutant human immunodeficiency virus type 1 strains with high degree of resistance to cynomolgus macaque TRIMCyp generated by random mutagenesis.

Tahmina Sultana1, Emi E Nakayama1, Satoshi Tobita1, Masaru Yokoyama2, Yohei Seki3, Akatsuki Saito3, Masako Nomaguchi4, Akio Adachi4, Hirofumi Akari3,5, Hironori Sato2, Tatsuo Shioda1.   

Abstract

Old World monkey TRIM5α strongly suppresses human immunodeficiency virus type 1 (HIV-1) replication. A fusion protein comprising cynomolgus macaque (CM) TRIM5 and cyclophilin A (CM TRIMCyp) also potently suppresses HIV-1 replication. However, CM TRIMCyp fails to suppress a mutant HIV-1 that encodes a mutant capsid protein containing a SIVmac239-derived loop between α-helices 4 and 5 (L4/5). There are seven amino acid differences between L4/5 of HIV-1 and SIVmac239. Here, we investigated the minimum numbers of amino acid substitutions that would allow HIV-1 to evade CM TRIMCyp-mediated suppression. We performed random PCR mutagenesis to construct a library of HIV-1 variants containing mutations in L4/5, and then we recovered replication-competent viruses from CD4+ MT4 cells that expressed high levels of CM TRIMCyp. CM TRIMCyp-resistant viruses were obtained after three rounds of selection in MT4 cells expressing CM TRIMCyp and these were found to contain four amino acid substitutions (H87R, A88G, P90D and P93A) in L4/5. We then confirmed that these substitutions were sufficient to confer CM TRIMCyp resistance to HIV-1. In a separate experiment using a similar method, we obtained novel CM TRIM5α-resistant HIV-1 strains after six rounds of selection and rescue. Analysis of these mutants revealed that V86A and G116E mutations in the capsid region conferred partial resistance to CM TRIM5α without substantial fitness cost when propagated in MT4 cells expressing CM TRIM5α. These results confirmed and further extended the previous notion that CM TRIMCyp and CM TRIM5α recognize the HIV-1 capsid in different manners.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26795727      PMCID: PMC4854368          DOI: 10.1099/jgv.0.000408

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  38 in total

1.  Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu.

Authors:  Stuart J D Neil; Trinity Zang; Paul D Bieniasz
Journal:  Nature       Date:  2008-01-16       Impact factor: 49.962

2.  Cyclophilin A-dependent restriction of human immunodeficiency virus type 1 capsid mutants for infection of nondividing cells.

Authors:  Mingli Qi; Ruifeng Yang; Christopher Aiken
Journal:  J Virol       Date:  2008-10-01       Impact factor: 5.103

3.  TRIM5 suppresses cross-species transmission of a primate immunodeficiency virus and selects for emergence of resistant variants in the new species.

Authors:  Andrea Kirmaier; Fan Wu; Ruchi M Newman; Laura R Hall; Jennifer S Morgan; Shelby O'Connor; Preston A Marx; Mareike Meythaler; Simoy Goldstein; Alicia Buckler-White; Amitinder Kaur; Vanessa M Hirsch; Welkin E Johnson
Journal:  PLoS Biol       Date:  2010-08-24       Impact factor: 8.029

4.  HIV-1 Vpu inhibits accumulation of the envelope glycoprotein within clathrin-coated, Gag-containing endosomes.

Authors:  Nanette Van Damme; John Guatelli
Journal:  Cell Microbiol       Date:  2007-12-10       Impact factor: 3.715

5.  Target cell type-dependent modulation of human immunodeficiency virus type 1 capsid disassembly by cyclophilin A.

Authors:  Yuan Li; Alak Kanti Kar; Joseph Sodroski
Journal:  J Virol       Date:  2009-08-05       Impact factor: 5.103

Review 6.  Anti-retroviral activity of TRIM5 alpha.

Authors:  Emi E Nakayama; Tatsuo Shioda
Journal:  Rev Med Virol       Date:  2010-03       Impact factor: 6.989

7.  The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys.

Authors:  Matthew Stremlau; Christopher M Owens; Michel J Perron; Michael Kiessling; Patrick Autissier; Joseph Sodroski
Journal:  Nature       Date:  2004-02-26       Impact factor: 49.962

8.  A single amino acid substitution of the human immunodeficiency virus type 1 capsid protein affects viral sensitivity to TRIM5 alpha.

Authors:  Ayumu Kuroishi; Katarzyna Bozek; Tatsuo Shioda; Emi E Nakayama
Journal:  Retrovirology       Date:  2010-07-07       Impact factor: 4.602

9.  Modification of a loop sequence between alpha-helices 6 and 7 of virus capsid (CA) protein in a human immunodeficiency virus type 1 (HIV-1) derivative that has simian immunodeficiency virus (SIVmac239) vif and CA alpha-helices 4 and 5 loop improves replication in cynomolgus monkey cells.

Authors:  Ayumu Kuroishi; Akatsuki Saito; Yasuhiro Shingai; Tatsuo Shioda; Masako Nomaguchi; Akio Adachi; Hirofumi Akari; Emi E Nakayama
Journal:  Retrovirology       Date:  2009-08-03       Impact factor: 4.602

10.  Active site remodeling switches HIV specificity of antiretroviral TRIMCyp.

Authors:  Amanda J Price; Flavia Marzetta; Michael Lammers; Laura M J Ylinen; Torsten Schaller; Sam J Wilson; Greg J Towers; Leo C James
Journal:  Nat Struct Mol Biol       Date:  2009-09-20       Impact factor: 15.369

View more
  7 in total

1.  Allosteric Regulation of HIV-1 Capsid Structure for Gag Assembly, Virion Production, and Viral Infectivity by a Disordered Interdomain Linker.

Authors:  Takaaki Koma; Osamu Kotani; Kei Miyakawa; Akihide Ryo; Masaru Yokoyama; Naoya Doi; Akio Adachi; Hironori Sato; Masako Nomaguchi
Journal:  J Virol       Date:  2019-08-13       Impact factor: 5.103

2.  Changes in dynamic and static structures of the HIV-1 p24 capsid protein N-domain caused by amino-acid substitution are associated with its viral viability.

Authors:  Yusuke Sato; Akimasa Matsugami; Satoru Watanabe; Fumiaki Hayashi; Munehito Arai; Takanori Kigawa; Chiaki Nishimura
Journal:  Protein Sci       Date:  2021-09-23       Impact factor: 6.725

3.  Naturally Occurring Mutations in HIV-1 CRF01_AE Capsid Affect Viral Sensitivity to Restriction Factors.

Authors:  Emi E Nakayama; Akatsuki Saito; Tahmina Sultana; Zhuan Jin; Kyotaro Nohata; Masato Shibata; Miho Hosoi; Kazushi Motomura; Tatsuo Shioda; Somchai Sangkitporn; Ruangchai Loket; Siriphan Saeng-Aroon
Journal:  AIDS Res Hum Retroviruses       Date:  2018-02-13       Impact factor: 2.205

4.  Multiple Pathways To Avoid Beta Interferon Sensitivity of HIV-1 by Mutations in Capsid.

Authors:  Tahmina Sultana; João I Mamede; Akatsuki Saito; Hirotaka Ode; Kyotaro Nohata; Romy Cohen; Emi E Nakayama; Yasumasa Iwatani; Masahiro Yamashita; Thomas J Hope; Tatsuo Shioda
Journal:  J Virol       Date:  2019-11-13       Impact factor: 5.103

Review 5.  HIV-1 capsid variability: viral exploitation and evasion of capsid-binding molecules.

Authors:  Akatsuki Saito; Masahiro Yamashita
Journal:  Retrovirology       Date:  2021-10-26       Impact factor: 4.602

6.  Targeting TRIM5α in HIV Cure Strategies for the CRISPR-Cas9 Era.

Authors:  Daryl Anne Victoria Weatherley; Michael Terence Boswell; Sarah L Rowland-Jones
Journal:  Front Immunol       Date:  2017-11-22       Impact factor: 7.561

7.  The 4th and 112th Residues of Viral Capsid Cooperatively Modulate Capsid-CPSF6 Interactions of HIV-1.

Authors:  Akatsuki Saito; Tahmina Sultana; Hirotaka Ode; Kyotaro Nohata; Yoshihiro Samune; Emi E Nakayama; Yasumasa Iwatani; Tatsuo Shioda
Journal:  AIDS Res Hum Retroviruses       Date:  2020-02-17       Impact factor: 2.205

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.